.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,656,722

« Back to Dashboard

Claims for Patent: 5,656,722

Title: A.sup.21 -, B.sup.30 - modified insulin derivatives having an altered action profile
Abstract:New insulin derivatives, the use thereof, and a pharmaceutical composition containing them Insulin derivatives having an isoelectric point between 5 and 8.5, or physiologically tolerated salts thereof, of the Formula II ##STR1## in which: R.sup.1 at position B1 denotes H or H-Phe; R.sup.2 at position A21 denotes a genetically encodable L-amino acid selected from the group consisting of Gly, Ala, Val, Leu, Ile, Pro, Phe, Trp, Met, Ser, Thr, Cys, Tyr, Asp, and Glu; R.sup.30 represents the residue of a neutral genetically encodable L-amino acid selected from the group consisting of Ala, Thr, and Ser; R.sup.31 represents 1, 2, or 3 neutral or basic alpha amino acids, wherein at least one of the alpha amino acids is selected from the group consisting of Arg, Lys, Hyl, Orn, Cit, and His; X represents His at position B10; and the sequences A1 to A20 and B1 to B29 in Formula II correspond to a mammalian insulin; excluding those insulin derivatives in which simultaneously: R.sup.1 at position B1 denotes Phe; and R.sup.3 is one alpha amino acid having a terminal carboxyl group.
Inventor(s): Dorschug; Michael (Bochum, DE)
Assignee: Hoechst Aktiengesellschaft (Frankfurt am Main, DE)
Application Number:08/304,593
Patent Claims: 1. An insulin derivative having an isoelectric point between 5 and 8.5, or a physiologically tolerated salt thereof, of the Formula II

in which: ##STR10## R.sup.1 at position B1 denotes H or H-Phe; R.sup.2 at position A21 denotes a genetically encodable L-amino acid selected from the group consisting of Gly, Ala, Val,

Leu, Ile, Pro, Phe, Trp, Met, Ser, Thr, Cys, Tyr, Asp, and Glu;

R.sup.30 represents the residue of a neutral genetically encodable L-amino acid selected from the group consisting of Ala, Thr, and Ser;

R.sup.31 represents 1, 2, or 3 neutral or basic .alpha.-amino acids, wherein at least one of the .alpha.-amino acids is selected from the group consisting of Arg, Lys, Hyl, Orn, Cit, and His;

X represents His at position B10; and the sequences A1 to A20 and B1 to B29 in Formula II correspond to a mammalian insulin;

excluding those insulin derivatives in which simultaneously:

R.sup.1 at position B1 denotes Phe; and

R.sup.31 is one alpha amino acid having a terminal carboxyl group.

2. An insulin derivative or the physiologically tolerated salts thereof as claimed in claim 1, wherein R.sup.1 in formula II represents H-Phe.

3. An insulin derivative or the physiologically tolerated salts thereof as claimed in claim 1, wherein R.sup.2 in formula II represents Gly, Ala, Ser, Thr, Asp, or Glu.

4. An insulin derivative or the physiologically tolerated salts thereof as claimed in claim 1, wherein R.sup.31 in formula II represents Arg-Arg-OH.

5. An insulin derivative or the physiologically tolerated salts thereof as claimed in claim 1, wherein the sequences (A1 to A20) and (B1 to B29) in formula II are the sequences of human, porcine, or bovine insulin.

6. A pharmaceutical composition that contains an effective amount of at least one insulin derivative of the formula II, or at least one of the physiologically tolerated salts thereof, as claimed in claim 1, in dissolved, amorphous or crystalline form for the treatment of diabetes.

7. A pharmaceutical composition as claimed in claim 6, which additionally contains 1 .mu.g to 2 mg of zinc/ml.

8. A pharmaceutical composition as claimed in claim 6, which additionally contains unmodified insulin.

9. A method for treating a patient suffering from diabetes mellitus, which comprises administering to said patient a pharmaceutical composition as claimed in claim 6.

10. An insulin derivative or the physiologically tolerated salts thereof as claimed in claim 3, wherein R.sup.2 in formula II represents Asp.

11. An insulin derivative or the physiologically tolerated salts thereof as claimed in claim 5, wherein the sequences (A1 to A20) and (B1 to B29) in formula II are the sequences of human insulin.

12. A pharmaceutical composition that contains an effective amount of at least one insulin derivative of the formula II, or at least one of the physiologically tolerated salts thereof, as claimed in claim 8, in dissolved form for the treatment of diabetes.

13. A pharmaceutical composition as claimed in claim 7, which additionally contains 5 .mu.g to 200 .mu.g of zinc/ml.

14. A pharmaceutical composition as claimed in claim 8, wherein said unmodified insulin is unmodified human insulin.

15. An insulin derivative or the physiologically tolerated salts thereof as claimed in claim 5, wherein R.sup.1 represents H-Phe, R.sup.2 represents Gly, R.sup.30 represents Thr, and R.sup.31 represents Arg-Arg-OH.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc